Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.
CYP2C9
capecitabine
celecoxib
drug-drug interaction
pharmacokinetics
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
03
05
2019
accepted:
12
06
2019
pubmed:
6
7
2019
medline:
20
8
2020
entrez:
6
7
2019
Statut:
ppublish
Résumé
This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate celecoxib, with implications for coadministration of fluoropyrimidines with CYP2C9 substrates such as warfarin. Patients received celecoxib 200 mg orally twice daily continuously, with capecitabine (1000 mg/m
Substances chimiques
Capecitabine
6804DJ8Z9U
CYP2C9 protein, human
EC 1.14.13.-
Cytochrome P-450 CYP2C9
EC 1.14.13.-
Celecoxib
JCX84Q7J1L
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1632-1640Subventions
Organisme : NIGMS NIH HHS
ID : U01GM061393
Pays : United States
Organisme : NCI NIH HHS
ID : K12CA139160
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA14599
Pays : United States
Informations de copyright
© 2019, The American College of Clinical Pharmacology.
Références
Venturini M. Rational development of capecitabine. Eur J Cancer. 2002;38(suppl 2):3-9.
Xeloda (capecitabine) tablets, for oral use [package insert]. South San Francisco, CA: Hoffman-La Roche, Inc.; 2016.
Brown MC. An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy. 1999;45(5):392-395.
Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction-a consecutive case series. Pharmacotherapy. 1999;19(12):1445-1449.
Masci G, Magagnoli M, Zucali PA, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol. 2003;21(4),736-739.
Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol. 2005;23(21):4719-4725.
Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. Pharmacotherapy. 2005;25(3):442-447.
Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005;5(3):175-180.
Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer. 2006;5(5):354-358.
Giunta G. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters: a review of the literature starting from a case report. Case Rep Med. 2010;2010:1-4.
Hata T, Kudo T, Sakai D, et al. Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer. Cancer Chemother Pharmacol. 2016;78(2):389-396.
Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2000;172(12):600-605.
Elbe JN, West BD, Link KP. A comparison of the isomers of warfarin. Biochem Pharmacol. 1966;15(7):1003-1006.
Lewis RJ, Trager WF, Chann KK, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974;53(6):1607-1617.
Choonara IA, Haynes BP, Cholerton S, Breckenridge AM, Park BK. Enantiomers of warfarin and vitamin K1 metabolism. Br J Clin Pharmacol. 1986;22(6):729-732.
Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol. 2003;59(5-6):407-409.
Konishi H, Yoshimoto T, Morita K, Minouchi T, Sato T, Yamaji A. Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. J Pharm Pharmacol. 2003;55(1):143-149.
Amiral J, Seghatchian J. Monitoring of anticoagulant therapy in cancer patients with thrombosis and the usefulness of blood activation markers. Transfus Apher Sci. 2017;56(3):279-286.
Celebrex (celecoxib) capsules [package insert]. New York, NY: Pfizer Inc.; 2005.
Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther. 2014;36(8):1253-1263.
Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000;293(2):453-459.
Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002;54(4):423-429.
Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000;28(3):308-314.
Celebrex (celecoxib capsules) [approval package]. New York, NY: G.D. Searle; 1998.
Clinical drug interaction studies-study design, data analysis, and clinical implications. Guidance for Industry. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-study-design-data-analysis-and-clinical-implications-guidance. Accesed June 7, 2019.
Wood K, Byron E, Janisch L, Salgia R, Sharma MR. Capecitabine and celecoxib as a promising therapy for thymic neoplasms. Am J Clin Oncol. 2018;41(10):963-966.
Miyazaki S, Satoh H, Ikenishi M, et al. Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine. Int J Clin Pharmacol Ther. 2016;54(9):657-665.
Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol. 2006;98(2):197-200.
Sager JE, Tripathy S, Price LS, et al. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6: simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017;123:85-96.
Zamek-Gliszczynski MJ, Mohutsky MA, Rehmel J, Ke AB. Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk. Drug Metab Dispos. 2014;42(6):1008-1015.
Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, Kim RB. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos. 2008;36(3):500-507.
Lim YP, Ma CY, Liu CL, et al. Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid Based Complement Alternat Med. 2012;2012:1-5.
Pan X, Lee YK, Jeong H. Farnesoid X receptor agonist represses cytochrome P450 2D6 expression by upregulating small heterodimer partner. Drug Metab Dispos. 2015;43(7):1002-1007.
Yu D, Green B, Marrone A, et al. Suppression of CYP2C9 by microRNA has-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep. 2015;5:8534.
Rieger JK, Reutter S, Hofmann U, Schwab M, Zanger UM. Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos. 2015;43(6):884-888.
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003;1619(3):243-253.
Chen Y, Goldstein JA. The transcriptional regulation of the human CYP2C genes. Curr Drug Metab. 2009;10(6):567-578.
Moscovitz JE, Kalgutkar AS, Nulick K, et al. Establishing transcriptional signatures to differentiate PXR-, CAR-, and AhR-mediated regulation of drug metabolism and transport genes in cryopreserved human hepatocytes. J Pharmacol Exp Ther. 2018; 365(2):262-271.
Hariparsad N, Ramsden D, Palamanda J, et al. Considerations from the IQ Induction Working Group in response to drug-drug interaction guidance from regulatory agencies: focus on downregulation, CYP2C induction, and CYP2B6 positive control. Drug Metab Dispos. 2017;45(10):1049-1059.
Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID. Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem. 1982;257(14):8171-8176.
Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104.
Yotsumoto K, Akiyoshi T, Wada N, Imaoka A, Ohtani H. 5-Fluorouracil treatment alters the expression of intestinal transporters in rat. Biopharm Drug Dispos. 2017;38(9):509-516.
Pagliarulo V, Ancona P, Niso M, et al. The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013;12:47.
Helsby NA, Lo WY, Thompson P, Laking GR. Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? Cancer Chemother Pharmacol. 2010;66(2):405-407.
Uppugunduri CR, Daali Y, Desmeules H, Dayer P, Krajinovic M, Ansari M. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab. 2012;13(8):1196-1204.
Kim SY, Kang JY, Hartman JH, et al. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012;6(3):157-164.
Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45(6):525-538.
Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol. 2003;43(1):84-91.
Dyar R, Hall S, McIntyre B. Warfarin prescription and administration: reducing the delay, improving the safety. BMJ Qual Improv Rep. 2015;4(1). pii: u204509.w1983.
Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol. 2015;11(8):1269-1279.